Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jun;13(3):257-267.
doi: 10.1007/s11523-018-0560-7.

Targeting BCL-2 in Hematologic Malignancies

Nadia Khan  1 , Brad Kahl  2
Affiliations
Review

Targeting BCL-2 in Hematologic Malignancies

Nadia Khan et al. Target Oncol. 2018 Jun.

Abstract

Resistance to apoptosis is one of the hallmarks of cancer and members of the B-cell lymphoma 2 (BCL-2) family of proteins are central regulators of apoptosis. Many cancers become resistant to chemotherapy and apoptosis by up-regulating BCL-2 and other family members, making these proteins attractive targets for cancer therapy. Venetoclax is an orally administered, small-molecule apoptosis stimulant that targets BCL-2 proteins by acting as a BCL-2 homology domain 3 (BH3) mimetic. The drug is approved in the USA and EU as a monotherapy for the for the treatment of certain patients with chronic lymphocytic leukemia (CLL) and is in phase III clinical development for multiple myeloma (MM), and in phase II or I/II clinical trials for acute myeloid leukemia, and several B-cell malignancies, including diffuse large B-cell lymphoma, Waldenstrom's macroglobulinaemia, follicular lymphoma, and mantle-cell lymphoma.

PubMed Disclaimer

References

    1. N Engl J Med. 2016 Jan 28;374(4):311-22 - PubMed
    1. Blood. 2004 May 1;103(9):3278-81 - PubMed
    1. J Clin Oncol. 2016 Nov 1;34(31):3758-3765 - PubMed
    1. Mol Cancer Ther. 2009 Apr;8(4):883-92 - PubMed
    1. J Clin Oncol. 2017 Mar 10;35(8):826-833 - PubMed

MeSH terms

Substances

LinkOut - more resources